3613 — Beijing Tong Ren Tang Chinese Medicine Co Share Price
Last trade - 00:00- HK$6.12bn
- HK$4.65bn
- HK$1.52bn
- 86
- 63
- 16
- 58
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 9.54 | ||
| PEG Ratio (f) | 0.7 | ||
| EPS Growth (f) | 15.74% | ||
| Dividend Yield (f) | 5.34% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.61 | ||
| Price to Tang. Book | 1.63 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 4.44 | ||
| EV to EBITDA | 7.28 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 13.63% | ||
| Return on Equity | 13.37% | ||
| Operating Margin | 40.17% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | HK$m | 1,432.63 | 1,315.35 | 1,556.16 | 1,731.1 | 1,524.94 | 1,628.17 | 1,850.4 | 0.15% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | -4.04 | -2.94 | +12.26 | +6.25 | -16.65 | +4.2 | +20.15 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Beijing Tong Ren Tang Chinese Medicine Company Limited is a company mainly engaged in the manufacturing and sale of Chinese medicine. Along with subsidiaries, it operates its business through three segments. The Hong Kong segment engages in the sale of Chinese medicine products and healthcare products and provision of Chinese medical consultation and treatments through retail outlets as well as wholesale of Chinese medicine products in Hong Kong. It is also involved in the royalty fee income from overseas entities using the brand of Tong Ren Tang. The Mainland China segment engages in the wholesale of healthcare products in Mainland China and the sole distribution of Tong Ren Tang branded products of Tong Ren Tang Technologies and Tong Ren Tang Ltd. to customers outside Mainland China. The Overseas segment engages in the retail and wholesale of Chinese medicine products and healthcare products and the provision of Chinese medical consultation and treatments in other overseas countries.
Directors
- Yong Ling Ding CHM (55)
- Fei Chen CEO (49)
- Fung Yi Tsang CFO (44)
- Man Lin COO (40)
- Ji Hong Hua DGM (41)
- Wai Yi Lam DGM (43)
- Xia Li OTH (48)
- Ngai Chi Chan NED (43)
- Zhong Zhen Zhao NED (58)
- Yok Sing Tsang NID (74)
- Last Annual
- December 31st, 2023
- Last Interim
- June 30th, 2024
- Incorporated
- March 18th, 2004
- Public Since
- May 7th, 2013
- No. of Employees
- 779
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Stock Exchange of Hong Kong Limited
- Shares in Issue
- 837,100,000
- Address
- Room 1405-1409, Office Tower,
- Web
- https://cm.tongrentang.com/
- Phone
- +852 null36575819
- Auditors
- PricewaterhouseCoopers
Upcoming Events for 3613
Similar to 3613
3D Medicines
Stock Exchange of Hong Kong Limited
3SBio
Stock Exchange of Hong Kong Limited
AIM Vaccine Co
Stock Exchange of Hong Kong Limited
Ascletis Pharma
Stock Exchange of Hong Kong Limited
Asymchem Laboratories Tianjin Co
Stock Exchange of Hong Kong Limited
FAQ
As of Today at 24:13 UTC, shares in Beijing Tong Ren Tang Chinese Medicine Co are trading at HK$7.31. This share price information is delayed by 15 minutes.
Shares in Beijing Tong Ren Tang Chinese Medicine Co last closed at HK$7.31 and the price had moved by -45.28% over the past 365 days. In terms of relative price strength the Beijing Tong Ren Tang Chinese Medicine Co share price has underperformed the FTSE Developed Asia Pacific Index by -48.96% over the past year.
The overall consensus recommendation for Beijing Tong Ren Tang Chinese Medicine Co is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreThe Beijing Tong Ren Tang Chinese Medicine Co dividend yield is 4.51% based on the trailing twelve month period.
Last year, Beijing Tong Ren Tang Chinese Medicine Co paid a total dividend of HK$0.33, and it currently has a trailing dividend yield of 4.51%. We do not have any data on when Beijing Tong Ren Tang Chinese Medicine Co is to next pay dividends.
We do not have data on when Beijing Tong Ren Tang Chinese Medicine Co is to next pay dividends. The historic dividend yield on Beijing Tong Ren Tang Chinese Medicine Co shares is currently 4.51%.
To buy shares in Beijing Tong Ren Tang Chinese Medicine Co you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of HK$7.31, shares in Beijing Tong Ren Tang Chinese Medicine Co had a market capitalisation of HK$6.12bn.
Here are the trading details for Beijing Tong Ren Tang Chinese Medicine Co:
- Country of listing: Hong Kong
- Exchange: HKG
- Ticker Symbol: 3613
Based on an overall assessment of its quality, value and momentum Beijing Tong Ren Tang Chinese Medicine Co is currently classified as a Contrarian. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Beijing Tong Ren Tang Chinese Medicine Co is HK$12.05. That is 64.84% above the last closing price of HK$7.31.
Analysts covering Beijing Tong Ren Tang Chinese Medicine Co currently have a consensus Earnings Per Share (EPS) forecast of HK$0.67 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Beijing Tong Ren Tang Chinese Medicine Co. Over the past six months, its share price has underperformed the FTSE Developed Asia Pacific Index by -24.54%.
As of the last closing price of HK$7.31, shares in Beijing Tong Ren Tang Chinese Medicine Co were trading -24.87% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Beijing Tong Ren Tang Chinese Medicine Co PE ratio based on its reported earnings over the past 12 months is 9.54. The shares last closed at HK$7.31.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Beijing Tong Ren Tang Chinese Medicine Co's management team is headed by:
- Yong Ling Ding - CHM
- Fei Chen - CEO
- Fung Yi Tsang - CFO
- Man Lin - COO
- Ji Hong Hua - DGM
- Wai Yi Lam - DGM
- Xia Li - OTH
- Ngai Chi Chan - NED
- Zhong Zhen Zhao - NED
- Yok Sing Tsang - NID